Article ; Online: Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
2022 Volume 34, Issue 1, Page(s) 187–189
Abstract: EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side events that are low grade in most cases. We report a case of severe cutaneous toxicity secondary to ... ...
| Abstract | EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side events that are low grade in most cases. We report a case of severe cutaneous toxicity secondary to cetuximab associated with bacterial cellulitis. A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients. Few days later, the patient becomes febrile, and the rash becomes more diffuse with a sandpaper appearance on the face, neck, chest, and flexor creases with exfoliation of large areas of skin. A bacterial cellulitis secondary to a dermatologic severe toxicity of Cetuximab was suspected. The patient started on antibiotics and local treatment with good response. This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities. |
|---|---|
| MeSH term(s) | Female ; Humans ; Middle Aged ; Cetuximab/adverse effects ; Antibodies, Monoclonal ; Cellulitis/chemically induced ; Cellulitis/drug therapy ; Drug Eruptions/drug therapy ; Drug Eruptions/etiology ; Drug Eruptions/prevention & control ; Colorectal Neoplasms/pathology ; Skin Diseases/chemically induced ; Exanthema/chemically induced ; Exanthema/drug therapy ; ErbB Receptors ; Bacteremia/chemically induced ; Bacteremia/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Fluorouracil/therapeutic use ; Leucovorin/therapeutic use |
| Chemical Substances | Cetuximab (PQX0D8J21J) ; Antibodies, Monoclonal ; ErbB Receptors (EC 2.7.10.1) ; Fluorouracil (U3P01618RT) ; Leucovorin (Q573I9DVLP) |
| Language | English |
| Publishing date | 2022-12-02 |
| Publishing country | England |
| Document type | Case Reports ; Journal Article |
| ZDB-ID | 1065301-6 |
| ISSN | 1473-5741 ; 0959-4973 |
| ISSN (online) | 1473-5741 |
| ISSN | 0959-4973 |
| DOI | 10.1097/CAD.0000000000001312 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3125: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.